共 23 条
[1]
Tefferi A(2016)Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management Am. J. Hematol. 91 1262-1271
[2]
Tefferi A(2000)Myelofibrosis with myeloid metaplasia N. Engl. J. Med. 342 1255-1265
[3]
Pardanani AD(2006)MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood 108 3472-3476
[4]
Cervantes F(2009)New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment Blood. 113 2895-2901
[5]
Passamonti F(2010)A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) Blood 115 1703-1708
[6]
Gangat N(2011)DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status J. Clin. Oncol. 29 392-397
[7]
Mudireddy M(2017)The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia Am. J. Hematol. 92 454-459
[8]
Arber DA(2016)The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia Blood 127 2391-2405
[9]
Mazzotta S(2006)Increased serum lactate dehydrogenase isoenzymes in Ph-negative chronic myeloproliferative diseases: a metabolic adaptation? Hematology 11 239-244
[10]
Woodliff HJ(1967)Serum lactic dehydrogenase activity in myeloproliferative and lymphoproliferative disorders Med. J. Aust. 1 431-432